Dividends, Diverse Product Pipelines, Acquisitions, Financial Results - Research Report on Quest Diagnostics, PerkinElmer, Waters, Alere, and TearLab

NEW YORK, September 3, 2013 /PRNewswire/ --

Editor Note: For more information about this release, please scroll to bottom.

Today, Analysts' Corner announced new research reports highlighting Quest Diagnostics Inc. (NYSE: DGX), PerkinElmer Inc. (NYSE: PKI), Waters Corp. (NYSE: WAT), Alere Inc. (NYSE: ALR), and TearLab Corporation (NASDAQ: TEAR). Today's readers may access these reports free of charge - including full price targets, industry analysis and analyst ratings - via the links below.

Quest Diagnostics Inc. Research Report

On August 20, 2013, Quest Diagnostics Inc.'s (Quest Diagnostics) Board of Directors has approved a quarterly cash dividend of $0.30 per share. The Company informed that the dividend is payable on October 16, 2013 to shareholders of record of the Company's common stock on October 1, 2013. The Full Research Report on Quest Diagnostics Inc. - including full detailed breakdown, analyst ratings and price targets - is available to download free of charge at: [http://www.analystscorner.com/r/full_research_report/05ba_DGX]

--

PerkinElmer Inc. Research Report

On August 29, 2013, PerkinElmer Inc. (PerkinElmer) announced the launch of the first commercially available screening test for Severe Combined Immunodeficiency (SCID) in Europe and the Middle East. According to the Company, the EnLite™ Neonatal TREC System - the new screening test widens the newborn screening portfolio of commercially available tests. Bobby Gaspar, M.D, Ph.D., Professor of Pediatrics and Immunology at London's Great Ormond Street Hospital for Children and the UCL Institute of Child Health said, "With the availability of PerkinElmer's new test for screening SCID, clinicians will be able to diagnose patients more quickly and precisely, improving quality of life and transplant outcome for newborns affected by this highly debilitating and potentially fatal condition." The Full Research Report on PerkinElmer Inc. - including full detailed breakdown, analyst ratings and price targets - is available to download free of charge at: [http://www.analystscorner.com/r/full_research_report/2016_PKI]

--

Waters Corp. Research Report

On August 7, 2013, Waters Corp. (Waters) announced that it has acquired Nonlinear Dynamics Ltd., a world leader in proteomics and metabolomics analysis software based in Newcastle upon Tyne, U.K.  Waters informed that with complex biological samples and more sensitive analytical techniques, managing experimental data continues to be a challenge and by acquiring Nonlinear Dynamics, the Company expects to address this challenge. Dr. Rohit Khanna, Vice President of Informatics and Worldwide Marketing for the Waters Division said, "The opportunity to combine Nonlinear Dynamics informatics expertise with Waters worldwide leadership in chromatography and mass spectrometry will continue to create significant benefits for omics-focused scientists and laboratories, Proteomics, metabolomics, and lipidomics hold vast potential for understanding the mechanisms of diseases, the development of innovative therapeutics, and discovering biomarkers for translational research." The Full Research Report on Waters Corp. - including full detailed breakdown, analyst ratings and price targets - is available to download free of charge at: [http://www.analystscorner.com/r/full_research_report/2fff_WAT]

--

Alere Inc. Research Report

On August 8, 2013, Alere Inc. reported that its subsidiary, Alere Analytics (Alere) has announced the launch of its Electronic Laboratory Reporting (ELR) Solution to aid hospitals in submitting reportable lab results to State Departments of Health.  As stated by the Company, the ELR solution is delivered on the Alere Analytics platform using a cloud-based, SaaS environment and it captures all codes associated with diseases, conditions, lab tests and demographic data by leveraging industry messaging standards, and then delivers this information to the appropriate state authority. Mansoor Khan, Sc.D., CEO of Alere commented, "In addition to continuing to work with State Departments of Health, we are now pleased to directly offer hospital labs in all states our proven ELR technology as a low-cost, simple and effective way to satisfy Meaningful Use Stage 2, as well as provide a comprehensive solution to improve efficiency, patient safety, and outcomes while maximizing reimbursements." The Full Research Report on Alere Inc. - including full detailed breakdown, analyst ratings and price targets - is available to download free of charge at: [http://www.analystscorner.com/r/full_research_report/5da1_ALR]

--

TearLab Corporation Research Report

On August 13, 2013, TearLab Corp. (TearLab) reported its Q2 2013 consolidated financial results with net revenues of $3.5 million, up 392.3% YoY. Loss from operations stood $5.3 million, in Q2 2013, compared to $2.5 million in Q2 2012. The Company's net loss for the quarter totaled $12 million or $0.41 per diluted share, compared to a net loss of $2 million or $0.10 per diluted share in Q2 2012. Elias Vamvakas, TearLab's CEO said, "We were very pleased with the strong level of support from both new and existing investors in our recent financing, This has provided us with necessary resources to continue expanding our sales organization, building widespread awareness and clinical use of the TearLab Osmolarity test, while creating an unprecedented partnership within the eye care community." The Full Research Report on TearLab Corporation - including full detailed breakdown, analyst ratings and price targets - is available to download free of charge at: [http://www.analystscorner.com/r/full_research_report/58d3_TEAR]

----

EDITOR NOTES:

COMPLIANCE PROCEDURE

Content is researched, written and reviewed on a best-effort basis. This document, article or report is prepared and authored by Equity News Network. An outsourced research services provider has, through Chartered Financial Analysts, only reviewed the information provided by Equity News Network in this article or report according to the Procedures outlined by Equity News Network. Equity News Network is not entitled to veto or interfere in the application of such procedures by the outsourced provider to the articles, documents or reports, as the case may be.

NOT FINANCIAL ADVICE

Equity News Network makes no warranty, expressed or implied, as to the accuracy or completeness or fitness for a purpose (investment or otherwise), of the information provided in this document. This information is not to be construed as personal financial advice. Readers are encouraged to consult their personal financial advisor before making any decisions to buy, sell or hold any securities mentioned herein.

NO WARRANTY OR LIABILITY ASSUMED

Equity News Network is not responsible for any error which may be occasioned at the time of printing of this document or any error, mistake or shortcoming. No liability is accepted by Equity News Network whatsoever for any direct, indirect or consequential loss arising from the use of this document. Equity News Network expressly disclaims any fiduciary responsibility or liability for any consequences, financial or otherwise arising from any reliance placed on the information in this document. Equity News Network does not (1) guarantee the accuracy, timeliness, completeness or correct sequencing of the information, or (2) warrant any results from use of the information. The included information is subject to change without notice.

http://www.analystscorner.com

SOURCE Analysts' Corner